Gut Microbiota Interactions in Inflammatory Bowel Disease

The gut microbiota, a complex assemblage of bacteria, archaea, fungi, viruses and protozoa, plays a central role in intestinal health by reinforcing the epithelial barrier, educating the mucosal immune system and producing bioactive metabolites. In inflammatory bowel disease (IBD), characterised by chronic relapsing inflammation of the gastrointestinal tract, marked shifts in microbial composition—termed dysbiosis—are accompanied by reduced diversity and loss of keystone species such as butyrate‐producers. This microbial imbalance undermines barrier integrity and fosters aberrant immune activation, with increased antigen presentation and pro‐inflammatory cytokine release. Microbial metabolites, notably short‐chain fatty acids, regulate T cell differentiation and epithelial repair, while host‐derived factors (for example, secretory immunoglobulin A, antimicrobial peptides and exosomal noncoding RNAs) shape community structure and function. Environmental influences including diet, antibiotics and stress further modulate these interactions. Deciphering the dynamic crosstalk between host and microbiota has led to novel approaches to reinstate homeostasis, encompassing dietary interventions, targeted small molecules, probiotics, prebiotics and microbial transplantation. These strategies hold promise to attenuate inflammation, restore barrier function and achieve precision management of IBD across diverse patient populations.

Research from Nature Portfolio

Experimental models have demonstrated that therapeutic restoration of microbial balance via transfer of healthy faecal communities leads to rapid attenuation of colonic inflammation through enhanced interleukin-10 production by both innate and adaptive immune cells. This intervention also reduces the antigen-presenting capacity of dendritic cells and macrophages, facilitating reinstatement of mucosal homeostasis. Another foundational study explored the impact of augmenting a butyrate-producing bacterium in chemically induced colitis. In the context of an already disrupted microbiota, this presumed probiotic failed to raise luminal butyrate levels and instead accelerated disease severity and mortality. The findings underscore the necessity of assessing candidate microbial therapies within inflamed ecosystems, as host-microbe and microbe-microbe interactions may diverge dramatically depending on pre-existing dysbiosis.

Gut Microbiota Interactions in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in gut microbiota interactions in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Dysbiosis: imbalance in the composition or function of the gut microbial community associated with disease.

Short-chain fatty acids (SCFAs): key metabolic products of microbial fermentation that regulate epithelial health and immune function.

Faecal microbiota transplantation (FMT): transfer of faecal material from a healthy donor to a recipient to restore microbiota equilibrium.

Exclusive enteral nutrition (EEN): a therapeutic diet replacing normal food with a defined liquid formula to induce remission in IBD.

Mucin-degrading bacteria: microbes that consume mucus glycans, influencing barrier integrity and immune activation.

References

1. An overview of host‐derived molecules that interact with gut microbiota. iMeta (2023).
2. Opposing diet, microbiome, and metabolite mechanisms regulate inflammatory bowel disease in a genetically susceptible host. Cell Host & Microbe (2024).
3. Regulation of Inflammation by Short Chain Fatty Acids. Nutrients (2011).
4. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nature Communications (2018).
5. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium. Scientific Reports (2016).